CAPTRUST Financial Advisors’s ADMA Biologics ADMA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$125K	Sell	14,891 -73,141	-83%	-$667K	﹤0.01%	2997
2026 Q1	$793K	Buy	88,032 +24,455	+38%	+$386K	﹤0.01%	1727
2025 Q4	$1.16M	Buy	63,577 +28,746	+83%	+$484K	﹤0.01%	1409
2025 Q3	$511K	Sell	34,831 -611	-2%	-$10.5K	﹤0.01%	1804
2025 Q2	$645K	Buy	+35,442	New	+$723K	﹤0.01%	1576
2022 Q3	–	Sell	-40	Closed	–	–	2086
2022 Q2	$0	Buy	+40	New	+$79	﹤0.01%	4911
2021 Q3	–	Sell	-1,084	Closed	-$2K	–	4619
2021 Q2	$2K	Buy	+1,084	New	+$1.91K	﹤0.01%	4136

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAPTRUST Financial Advisors's ADMA Position: Q2 2026 in Review

CAPTRUST Financial Advisors reduced its ADMA Biologics (ADMA) stake by 83% in Q2 2026, selling an estimated $667K and leaving 14,891 shares worth $125K. The position accounts for ﹤0.01% of the portfolio, ranked #2997.

CAPTRUST Financial Advisors first reported a position in ADMA in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.16M in Q4 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

CAPTRUST Financial Advisors held 14,891 shares of ADMA Biologics worth $125K as of Q2 2026.
CAPTRUST Financial Advisors sold 73,141 ADMA Biologics shares in Q2 2026, an estimated $667K.
ADMA Biologics made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2997 holding.
CAPTRUST Financial Advisors first reported a position in ADMA Biologics in Q2 2021 and has held it in 7 quarters since.
CAPTRUST Financial Advisors's ADMA Biologics position peaked at $1.16M in Q4 2025.
323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.